Robert Griffin
Concepts (742)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 38 | 2024 | 1314 | 4.960 |
Why?
| | Hyperthermia, Induced | 17 | 2019 | 114 | 3.440 |
Why?
| | Mammary Neoplasms, Experimental | 12 | 2015 | 122 | 3.080 |
Why?
| | Radiotherapy | 10 | 2021 | 128 | 2.800 |
Why?
| | Air Pollutants | 13 | 2024 | 78 | 2.720 |
Why?
| | Gold | 9 | 2023 | 81 | 2.520 |
Why?
| | Bystander Effect | 5 | 2024 | 24 | 1.980 |
Why?
| | Mice | 74 | 2024 | 5899 | 1.960 |
Why?
| | Radiation-Sensitizing Agents | 11 | 2023 | 50 | 1.940 |
Why?
| | Animals | 100 | 2024 | 13485 | 1.900 |
Why?
| | Nanostructures | 5 | 2023 | 41 | 1.750 |
Why?
| | Cell Line, Tumor | 38 | 2024 | 1429 | 1.620 |
Why?
| | Exosomes | 7 | 2022 | 56 | 1.560 |
Why?
| | Angiogenesis Inhibitors | 8 | 2017 | 183 | 1.490 |
Why?
| | Phototherapy | 5 | 2022 | 26 | 1.490 |
Why?
| | Radiation Tolerance | 9 | 2020 | 78 | 1.450 |
Why?
| | Metal Nanoparticles | 4 | 2023 | 66 | 1.410 |
Why?
| | Blood Vessels | 9 | 2020 | 73 | 1.390 |
Why?
| | Nanoparticles | 6 | 2022 | 131 | 1.380 |
Why?
| | Neoplasms, Experimental | 6 | 2020 | 111 | 1.340 |
Why?
| | Lung Neoplasms | 10 | 2024 | 643 | 1.330 |
Why?
| | Galectin 1 | 4 | 2017 | 19 | 1.320 |
Why?
| | Environmental Monitoring | 8 | 2024 | 76 | 1.290 |
Why?
| | Aerosols | 10 | 2023 | 74 | 1.290 |
Why?
| | Oxygen | 12 | 2020 | 332 | 1.260 |
Why?
| | Polyethylene Glycols | 4 | 2022 | 93 | 1.220 |
Why?
| | Air Pollution | 3 | 2024 | 51 | 1.180 |
Why?
| | Particulate Matter | 5 | 2024 | 70 | 1.170 |
Why?
| | Carcinoma, Squamous Cell | 6 | 2019 | 331 | 1.160 |
Why?
| | Humans | 113 | 2025 | 52441 | 1.060 |
Why?
| | Combined Modality Therapy | 17 | 2022 | 641 | 1.060 |
Why?
| | Endothelial Cells | 7 | 2021 | 283 | 1.030 |
Why?
| | Tumor Necrosis Factor-alpha | 8 | 2019 | 390 | 0.980 |
Why?
| | Proteins | 7 | 2023 | 353 | 0.950 |
Why?
| | Sulfates | 2 | 2023 | 27 | 0.950 |
Why?
| | Neovascularization, Pathologic | 9 | 2021 | 158 | 0.950 |
Why?
| | Apoptosis | 10 | 2024 | 1120 | 0.940 |
Why?
| | Antineoplastic Agents | 13 | 2024 | 1216 | 0.870 |
Why?
| | Radiosurgery | 7 | 2024 | 130 | 0.860 |
Why?
| | Liposomes | 2 | 2022 | 53 | 0.860 |
Why?
| | Oxygen Consumption | 4 | 2020 | 193 | 0.850 |
Why?
| | Peptides | 10 | 2022 | 239 | 0.830 |
Why?
| | Fibrosarcoma | 6 | 2019 | 15 | 0.830 |
Why?
| | Ozone | 6 | 2022 | 23 | 0.830 |
Why?
| | Benzeneacetamides | 2 | 2024 | 12 | 0.810 |
Why?
| | Glutaminase | 2 | 2024 | 18 | 0.810 |
Why?
| | Fluorescent Dyes | 5 | 2022 | 91 | 0.810 |
Why?
| | Diamond | 1 | 2023 | 1 | 0.810 |
Why?
| | Microwaves | 1 | 2023 | 10 | 0.810 |
Why?
| | Cell Communication | 3 | 2021 | 74 | 0.800 |
Why?
| | Mice, Inbred BALB C | 8 | 2020 | 304 | 0.800 |
Why?
| | Radiotherapy, Intensity-Modulated | 5 | 2022 | 184 | 0.770 |
Why?
| | Neoplastic Cells, Circulating | 3 | 2017 | 34 | 0.760 |
Why?
| | Pyrimidines | 10 | 2024 | 199 | 0.760 |
Why?
| | Indocyanine Green | 2 | 2013 | 29 | 0.750 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 177 | 0.730 |
Why?
| | Flow Cytometry | 5 | 2017 | 396 | 0.720 |
Why?
| | Protein Kinase Inhibitors | 6 | 2024 | 231 | 0.690 |
Why?
| | Cell Survival | 16 | 2024 | 598 | 0.680 |
Why?
| | Thiadiazoles | 3 | 2024 | 18 | 0.680 |
Why?
| | Conservation of Natural Resources | 6 | 2025 | 44 | 0.660 |
Why?
| | Models, Theoretical | 9 | 2017 | 181 | 0.660 |
Why?
| | Antioxidants | 2 | 2020 | 255 | 0.640 |
Why?
| | Radiotherapy Dosage | 7 | 2022 | 256 | 0.640 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 7 | 2023 | 262 | 0.630 |
Why?
| | Radiation-Protective Agents | 1 | 2020 | 69 | 0.630 |
Why?
| | Immunotherapy | 2 | 2021 | 251 | 0.620 |
Why?
| | Radiation Dosage | 2 | 2020 | 160 | 0.620 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 289 | 0.600 |
Why?
| | Epigenesis, Genetic | 2 | 2019 | 396 | 0.580 |
Why?
| | Ecosystem | 5 | 2017 | 99 | 0.570 |
Why?
| | Molecular Imaging | 2 | 2015 | 28 | 0.570 |
Why?
| | Information Dissemination | 2 | 2016 | 84 | 0.570 |
Why?
| | Drug Delivery Systems | 2 | 2022 | 148 | 0.570 |
Why?
| | Aniline Compounds | 5 | 2024 | 47 | 0.570 |
Why?
| | Arsenicals | 3 | 2007 | 15 | 0.560 |
Why?
| | Cell Proliferation | 12 | 2024 | 1013 | 0.560 |
Why?
| | Oxides | 3 | 2007 | 21 | 0.560 |
Why?
| | Female | 38 | 2022 | 28277 | 0.550 |
Why?
| | Uncertainty | 2 | 2022 | 45 | 0.550 |
Why?
| | Disease Models, Animal | 11 | 2020 | 1483 | 0.540 |
Why?
| | Xenograft Model Antitumor Assays | 13 | 2021 | 218 | 0.540 |
Why?
| | Gamma Rays | 2 | 2020 | 48 | 0.530 |
Why?
| | Bone and Bones | 2 | 2012 | 492 | 0.530 |
Why?
| | Oxidation-Reduction | 5 | 2023 | 327 | 0.530 |
Why?
| | Radiotherapy, Conformal | 2 | 2019 | 52 | 0.520 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 175 | 0.520 |
Why?
| | Coronavirus Infections | 1 | 2020 | 188 | 0.510 |
Why?
| | Science | 1 | 2016 | 21 | 0.510 |
Why?
| | Wind | 3 | 2025 | 7 | 0.510 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 135 | 0.510 |
Why?
| | Radiobiology | 5 | 2023 | 21 | 0.500 |
Why?
| | Mice, Nude | 11 | 2019 | 230 | 0.490 |
Why?
| | Enzyme Inhibitors | 7 | 2024 | 378 | 0.490 |
Why?
| | Mouth Neoplasms | 4 | 2015 | 22 | 0.480 |
Why?
| | Texas | 7 | 2024 | 137 | 0.470 |
Why?
| | Pandemics | 1 | 2020 | 580 | 0.470 |
Why?
| | Cell Hypoxia | 6 | 2015 | 82 | 0.460 |
Why?
| | Carcinoma | 2 | 2013 | 135 | 0.440 |
Why?
| | Laser Therapy | 2 | 2013 | 74 | 0.440 |
Why?
| | Exons | 3 | 2024 | 101 | 0.430 |
Why?
| | Solanum tuberosum | 1 | 2014 | 5 | 0.430 |
Why?
| | Sanitation | 1 | 2014 | 17 | 0.430 |
Why?
| | Radiation Oncology | 3 | 2024 | 26 | 0.420 |
Why?
| | Bone Marrow Neoplasms | 1 | 2013 | 13 | 0.420 |
Why?
| | Coloring Agents | 2 | 2013 | 68 | 0.420 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2018 | 853 | 0.410 |
Why?
| | Chemokines | 1 | 2013 | 77 | 0.410 |
Why?
| | Spectrum Analysis, Raman | 3 | 2019 | 42 | 0.410 |
Why?
| | Plasmodium falciparum | 2 | 2024 | 23 | 0.400 |
Why?
| | Malaria, Falciparum | 2 | 2024 | 21 | 0.400 |
Why?
| | Infrared Rays | 2 | 2019 | 21 | 0.400 |
Why?
| | Tumor Cells, Cultured | 8 | 2019 | 441 | 0.390 |
Why?
| | Signal Transduction | 8 | 2021 | 1724 | 0.390 |
Why?
| | Indoles | 4 | 2024 | 283 | 0.380 |
Why?
| | Antibodies, Monoclonal | 3 | 2020 | 475 | 0.370 |
Why?
| | Adult Stem Cells | 1 | 2012 | 11 | 0.370 |
Why?
| | Tumor Microenvironment | 6 | 2022 | 257 | 0.370 |
Why?
| | DNA Damage | 5 | 2019 | 298 | 0.370 |
Why?
| | Lignin | 1 | 2011 | 2 | 0.360 |
Why?
| | Environmental Pollution | 1 | 2011 | 14 | 0.360 |
Why?
| | Bone Neoplasms | 2 | 2011 | 188 | 0.360 |
Why?
| | Mice, Inbred C3H | 9 | 2015 | 80 | 0.350 |
Why?
| | Models, Biological | 6 | 2018 | 735 | 0.350 |
Why?
| | Dose-Response Relationship, Radiation | 10 | 2020 | 185 | 0.350 |
Why?
| | Time Factors | 11 | 2017 | 2987 | 0.340 |
Why?
| | Photochemical Processes | 1 | 2010 | 5 | 0.340 |
Why?
| | Saliva | 3 | 2007 | 56 | 0.340 |
Why?
| | Photons | 2 | 2020 | 20 | 0.340 |
Why?
| | Cytokines | 1 | 2013 | 622 | 0.330 |
Why?
| | Phenols | 1 | 2011 | 96 | 0.330 |
Why?
| | Breast Neoplasms | 6 | 2017 | 1203 | 0.330 |
Why?
| | Melanoma, Experimental | 2 | 2021 | 34 | 0.320 |
Why?
| | Cell Line | 6 | 2021 | 1020 | 0.320 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2025 | 234 | 0.320 |
Why?
| | Rats | 11 | 2022 | 3228 | 0.320 |
Why?
| | Magnetic Resonance Spectroscopy | 2 | 2023 | 249 | 0.320 |
Why?
| | Mutagenesis, Insertional | 3 | 2024 | 24 | 0.320 |
Why?
| | Methionine | 3 | 2020 | 142 | 0.320 |
Why?
| | Oceans and Seas | 3 | 2025 | 29 | 0.310 |
Why?
| | Radiation Injuries | 3 | 2020 | 114 | 0.310 |
Why?
| | Volatile Organic Compounds | 2 | 2022 | 8 | 0.300 |
Why?
| | Hydroxyl Radical | 2 | 2010 | 6 | 0.300 |
Why?
| | Glutamine | 3 | 2024 | 177 | 0.300 |
Why?
| | Atmosphere | 4 | 2019 | 11 | 0.300 |
Why?
| | Receptor, erbB-2 | 5 | 2016 | 79 | 0.290 |
Why?
| | Reactive Oxygen Species | 3 | 2024 | 415 | 0.290 |
Why?
| | Radiation | 2 | 2020 | 14 | 0.290 |
Why?
| | Drug Carriers | 2 | 2013 | 68 | 0.290 |
Why?
| | Weightlessness Simulation | 2 | 2020 | 22 | 0.290 |
Why?
| | Male | 22 | 2024 | 26874 | 0.280 |
Why?
| | Precancerous Conditions | 2 | 2010 | 87 | 0.280 |
Why?
| | History, 20th Century | 3 | 2020 | 100 | 0.280 |
Why?
| | Caspase Inhibitors | 1 | 2008 | 16 | 0.280 |
Why?
| | Cell Membrane Permeability | 1 | 2008 | 24 | 0.280 |
Why?
| | Mice, SCID | 3 | 2024 | 178 | 0.280 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 28 | 0.270 |
Why?
| | Cities | 3 | 2024 | 32 | 0.270 |
Why?
| | Cell Death | 6 | 2019 | 169 | 0.270 |
Why?
| | Forecasting | 4 | 2020 | 151 | 0.270 |
Why?
| | China | 3 | 2023 | 135 | 0.270 |
Why?
| | Nanomedicine | 2 | 2024 | 15 | 0.270 |
Why?
| | Carbon Radioisotopes | 2 | 2024 | 54 | 0.270 |
Why?
| | Freezing | 2 | 2004 | 15 | 0.270 |
Why?
| | Caspases | 1 | 2007 | 101 | 0.270 |
Why?
| | Adenocarcinoma | 1 | 2011 | 403 | 0.270 |
Why?
| | Nanotubes, Carbon | 2 | 2017 | 43 | 0.260 |
Why?
| | Vascular Neoplasms | 1 | 2007 | 17 | 0.260 |
Why?
| | Fisheries | 2 | 2025 | 10 | 0.260 |
Why?
| | Radiotherapy, Image-Guided | 2 | 2016 | 25 | 0.250 |
Why?
| | Glutathione | 2 | 2019 | 301 | 0.250 |
Why?
| | Microscopy, Fluorescence | 3 | 2018 | 140 | 0.250 |
Why?
| | Melanoma | 2 | 2020 | 272 | 0.250 |
Why?
| | Risk Assessment | 3 | 2017 | 1349 | 0.250 |
Why?
| | Brain | 3 | 2025 | 1337 | 0.240 |
Why?
| | Cryotherapy | 2 | 2011 | 12 | 0.240 |
Why?
| | Radiometry | 3 | 2016 | 125 | 0.230 |
Why?
| | Organs at Risk | 3 | 2022 | 75 | 0.230 |
Why?
| | Energy-Generating Resources | 1 | 2025 | 1 | 0.230 |
Why?
| | Renewable Energy | 1 | 2025 | 2 | 0.230 |
Why?
| | Hindlimb | 2 | 2004 | 31 | 0.230 |
Why?
| | Tyrosine-tRNA Ligase | 1 | 2024 | 1 | 0.230 |
Why?
| | Ovarian Neoplasms | 2 | 2008 | 455 | 0.230 |
Why?
| | Administration, Oral | 6 | 2024 | 455 | 0.220 |
Why?
| | Hydrogen-Ion Concentration | 5 | 2005 | 178 | 0.220 |
Why?
| | Doxorubicin | 2 | 2024 | 246 | 0.220 |
Why?
| | Antimalarials | 1 | 2024 | 33 | 0.220 |
Why?
| | Cell Culture Techniques | 2 | 2019 | 97 | 0.220 |
Why?
| | Disease Progression | 4 | 2019 | 870 | 0.220 |
Why?
| | Oxidants, Photochemical | 1 | 2004 | 3 | 0.210 |
Why?
| | Endocytosis | 1 | 2024 | 52 | 0.210 |
Why?
| | Smog | 1 | 2004 | 5 | 0.210 |
Why?
| | Floods | 2 | 2021 | 3 | 0.210 |
Why?
| | Clinical Trials as Topic | 3 | 2023 | 461 | 0.210 |
Why?
| | Porphyrins | 1 | 2023 | 9 | 0.210 |
Why?
| | Oxidants | 1 | 2004 | 51 | 0.210 |
Why?
| | Vascular Endothelial Growth Factor A | 5 | 2017 | 186 | 0.210 |
Why?
| | Nitroimidazoles | 2 | 2015 | 16 | 0.210 |
Why?
| | Proteomics | 4 | 2021 | 332 | 0.210 |
Why?
| | Photochemotherapy | 1 | 2023 | 32 | 0.200 |
Why?
| | Sulfur Oxides | 1 | 2023 | 1 | 0.200 |
Why?
| | Gulf of Mexico | 1 | 2023 | 7 | 0.200 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2008 | 51 | 0.200 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2023 | 208 | 0.200 |
Why?
| | Proteasome Endopeptidase Complex | 2 | 2021 | 137 | 0.200 |
Why?
| | Partial Pressure | 3 | 2011 | 14 | 0.200 |
Why?
| | Tumor Burden | 3 | 2010 | 132 | 0.200 |
Why?
| | Halogens | 1 | 2022 | 3 | 0.200 |
Why?
| | Phosphatidylethanolamines | 1 | 2022 | 10 | 0.200 |
Why?
| | Organic Anion Transporters | 1 | 2022 | 1 | 0.200 |
Why?
| | Lipid Bilayers | 1 | 2022 | 12 | 0.190 |
Why?
| | Bile | 1 | 2022 | 23 | 0.190 |
Why?
| | Chloral Hydrate | 1 | 2022 | 18 | 0.190 |
Why?
| | Environmental Exposure | 2 | 2022 | 225 | 0.190 |
Why?
| | Parasites | 1 | 2002 | 3 | 0.190 |
Why?
| | Water Pollution | 1 | 2002 | 9 | 0.190 |
Why?
| | Glucocorticoids | 2 | 2022 | 234 | 0.190 |
Why?
| | Tissue Distribution | 1 | 2022 | 175 | 0.190 |
Why?
| | Protein Binding | 5 | 2020 | 673 | 0.190 |
Why?
| | Receptors, Growth Factor | 1 | 2002 | 7 | 0.190 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2002 | 8 | 0.190 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 2002 | 5 | 0.190 |
Why?
| | Biological Transport | 2 | 2021 | 153 | 0.190 |
Why?
| | X-Rays | 3 | 2016 | 55 | 0.190 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 3 | 2007 | 11 | 0.190 |
Why?
| | Low Back Pain | 1 | 2022 | 31 | 0.190 |
Why?
| | Naphthoquinones | 3 | 2007 | 10 | 0.190 |
Why?
| | Bone Resorption | 2 | 2022 | 300 | 0.180 |
Why?
| | Liver Neoplasms | 2 | 2023 | 341 | 0.180 |
Why?
| | Protons | 1 | 2022 | 74 | 0.180 |
Why?
| | Cholesterol | 1 | 2022 | 159 | 0.180 |
Why?
| | Pyrroles | 1 | 2002 | 73 | 0.180 |
Why?
| | Boron Compounds | 1 | 2021 | 19 | 0.180 |
Why?
| | Postmenopause | 1 | 2022 | 104 | 0.180 |
Why?
| | Neoplasm Proteins | 3 | 2017 | 328 | 0.180 |
Why?
| | Nucleotides, Cyclic | 1 | 2021 | 5 | 0.180 |
Why?
| | Spheroids, Cellular | 3 | 2019 | 26 | 0.180 |
Why?
| | High-Intensity Focused Ultrasound Ablation | 2 | 2011 | 14 | 0.180 |
Why?
| | Optical Imaging | 2 | 2020 | 25 | 0.170 |
Why?
| | Endosomes | 1 | 2021 | 34 | 0.170 |
Why?
| | Bone Remodeling | 1 | 2022 | 151 | 0.170 |
Why?
| | Radiation, Ionizing | 4 | 2018 | 96 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2021 | 23 | 0.170 |
Why?
| | Cells, Cultured | 4 | 2020 | 1583 | 0.170 |
Why?
| | Proteasome Inhibitors | 1 | 2021 | 101 | 0.170 |
Why?
| | Proprioception | 1 | 2020 | 7 | 0.170 |
Why?
| | Ankle | 1 | 2020 | 15 | 0.170 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 60 | 0.170 |
Why?
| | Spectrum Analysis | 1 | 2020 | 50 | 0.170 |
Why?
| | Proton Therapy | 1 | 2020 | 12 | 0.170 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 187 | 0.170 |
Why?
| | Thymus Gland | 1 | 2020 | 40 | 0.170 |
Why?
| | Chronic Pain | 1 | 2023 | 189 | 0.160 |
Why?
| | History, 21st Century | 1 | 2020 | 60 | 0.160 |
Why?
| | Neural Stem Cells | 1 | 2020 | 25 | 0.160 |
Why?
| | Cell Differentiation | 2 | 2020 | 667 | 0.160 |
Why?
| | Adenosine Triphosphate | 1 | 2021 | 234 | 0.160 |
Why?
| | Heavy Ion Radiotherapy | 1 | 2019 | 2 | 0.160 |
Why?
| | Receptor, TIE-2 | 2 | 2017 | 16 | 0.160 |
Why?
| | Spleen | 1 | 2020 | 166 | 0.160 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2019 | 10 | 0.160 |
Why?
| | Osteogenesis | 1 | 2022 | 368 | 0.160 |
Why?
| | Public Health | 1 | 2002 | 224 | 0.160 |
Why?
| | Calixarenes | 2 | 2017 | 9 | 0.160 |
Why?
| | Whole-Body Irradiation | 1 | 2020 | 128 | 0.160 |
Why?
| | Societies, Medical | 1 | 2020 | 200 | 0.160 |
Why?
| | Autoantibodies | 1 | 2020 | 118 | 0.160 |
Why?
| | Interleukin-6 | 2 | 2020 | 271 | 0.150 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2020 | 141 | 0.150 |
Why?
| | Cone-Beam Computed Tomography | 2 | 2016 | 34 | 0.150 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 1507 | 0.150 |
Why?
| | Cyclonic Storms | 2 | 2017 | 8 | 0.150 |
Why?
| | Drug Evaluation, Preclinical | 3 | 2015 | 141 | 0.150 |
Why?
| | Preservation, Biological | 1 | 2018 | 9 | 0.150 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 86 | 0.150 |
Why?
| | Membrane Proteins | 1 | 2021 | 344 | 0.150 |
Why?
| | Ephrin-B2 | 1 | 2018 | 5 | 0.150 |
Why?
| | Astrocytes | 1 | 2020 | 148 | 0.150 |
Why?
| | Paracrine Communication | 1 | 2018 | 13 | 0.150 |
Why?
| | Methionine Adenosyltransferase | 1 | 2018 | 19 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 140 | 0.150 |
Why?
| | Environmental Pollutants | 1 | 2020 | 104 | 0.150 |
Why?
| | Cystic Fibrosis | 1 | 2021 | 160 | 0.150 |
Why?
| | Treatment Outcome | 5 | 2020 | 5508 | 0.140 |
Why?
| | Biological Assay | 1 | 2018 | 38 | 0.140 |
Why?
| | Microinjections | 1 | 2018 | 35 | 0.140 |
Why?
| | Myocytes, Cardiac | 1 | 2019 | 146 | 0.140 |
Why?
| | Receptors, Fc | 1 | 2018 | 10 | 0.140 |
Why?
| | Lipopolysaccharides | 1 | 2019 | 205 | 0.140 |
Why?
| | Calibration | 1 | 2018 | 56 | 0.140 |
Why?
| | Prostatic Neoplasms | 2 | 2013 | 398 | 0.140 |
Why?
| | Galectins | 1 | 2018 | 7 | 0.140 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2018 | 47 | 0.140 |
Why?
| | Ubiquitin-Activating Enzymes | 1 | 2018 | 3 | 0.140 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2018 | 106 | 0.140 |
Why?
| | Nucleosides | 1 | 2018 | 5 | 0.140 |
Why?
| | Indazoles | 1 | 2018 | 47 | 0.140 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 110 | 0.140 |
Why?
| | Erythrocyte Membrane | 1 | 2017 | 14 | 0.140 |
Why?
| | California | 4 | 2010 | 92 | 0.140 |
Why?
| | Particle Size | 2 | 2024 | 76 | 0.140 |
Why?
| | Structure-Activity Relationship | 7 | 2021 | 399 | 0.140 |
Why?
| | Scavenger Receptors, Class E | 1 | 2019 | 200 | 0.140 |
Why?
| | MicroRNAs | 1 | 2021 | 392 | 0.130 |
Why?
| | Small Molecule Libraries | 1 | 2018 | 66 | 0.130 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2017 | 35 | 0.130 |
Why?
| | Models, Molecular | 4 | 2021 | 356 | 0.130 |
Why?
| | Natural Science Disciplines | 1 | 2017 | 2 | 0.130 |
Why?
| | Muscle, Skeletal | 2 | 2020 | 799 | 0.130 |
Why?
| | United States | 5 | 2025 | 5215 | 0.130 |
Why?
| | Epitope Mapping | 1 | 2017 | 6 | 0.130 |
Why?
| | Vehicle Emissions | 1 | 2017 | 10 | 0.130 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 22 | 0.130 |
Why?
| | Silver | 1 | 2017 | 48 | 0.130 |
Why?
| | Bacteria | 1 | 2018 | 223 | 0.130 |
Why?
| | Pyridazines | 2 | 2008 | 10 | 0.130 |
Why?
| | Ammonia | 1 | 2017 | 87 | 0.130 |
Why?
| | Random Allocation | 2 | 2015 | 286 | 0.130 |
Why?
| | Sulfonamides | 1 | 2018 | 137 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 1020 | 0.130 |
Why?
| | Myocardial Infarction | 1 | 2021 | 449 | 0.130 |
Why?
| | Epithelial Cells | 1 | 2018 | 217 | 0.130 |
Why?
| | Biomass | 1 | 2016 | 22 | 0.130 |
Why?
| | Social Environment | 1 | 2017 | 82 | 0.130 |
Why?
| | Dendritic Cells | 1 | 2017 | 132 | 0.130 |
Why?
| | Antibodies | 1 | 2017 | 144 | 0.130 |
Why?
| | Mice, Inbred Strains | 3 | 2013 | 165 | 0.130 |
Why?
| | Linear Models | 2 | 2016 | 288 | 0.120 |
Why?
| | Radiation Protection | 1 | 2016 | 46 | 0.120 |
Why?
| | Computer Simulation | 4 | 2025 | 285 | 0.120 |
Why?
| | Extraterrestrial Environment | 1 | 2016 | 7 | 0.120 |
Why?
| | Neoplasm Transplantation | 2 | 2007 | 86 | 0.120 |
Why?
| | Chemistry, Organic | 2 | 2019 | 2 | 0.120 |
Why?
| | Multiple Myeloma | 1 | 2010 | 3013 | 0.120 |
Why?
| | Organ Specificity | 1 | 2016 | 116 | 0.120 |
Why?
| | Extracellular Fluid | 1 | 2015 | 14 | 0.120 |
Why?
| | Tomography, Spiral Computed | 1 | 2016 | 56 | 0.120 |
Why?
| | Microbubbles | 1 | 2015 | 27 | 0.120 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2016 | 89 | 0.120 |
Why?
| | Organ Sparing Treatments | 1 | 2016 | 58 | 0.120 |
Why?
| | Sulfuric Acids | 1 | 2015 | 8 | 0.120 |
Why?
| | Cell Count | 1 | 2015 | 143 | 0.120 |
Why?
| | Stromal Cells | 1 | 2015 | 76 | 0.110 |
Why?
| | Pressure | 1 | 2015 | 100 | 0.110 |
Why?
| | Rabbits | 3 | 2010 | 370 | 0.110 |
Why?
| | Necrosis | 3 | 2013 | 169 | 0.110 |
Why?
| | Biomedical Research | 1 | 2018 | 260 | 0.110 |
Why?
| | Tandem Mass Spectrometry | 3 | 2017 | 255 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 150 | 0.110 |
Why?
| | Carbon Dioxide | 2 | 2005 | 95 | 0.110 |
Why?
| | Cisplatin | 2 | 2024 | 282 | 0.110 |
Why?
| | Contrast Media | 1 | 2015 | 173 | 0.110 |
Why?
| | Mexico | 1 | 2014 | 36 | 0.110 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 506 | 0.110 |
Why?
| | Hot Temperature | 3 | 2013 | 203 | 0.110 |
Why?
| | HEK293 Cells | 3 | 2020 | 236 | 0.100 |
Why?
| | Animals, Inbred Strains | 1 | 2013 | 5 | 0.100 |
Why?
| | DNA Methylation | 1 | 2018 | 573 | 0.100 |
Why?
| | Ultrasonography | 1 | 2015 | 416 | 0.100 |
Why?
| | Nanoconjugates | 1 | 2013 | 1 | 0.100 |
Why?
| | Ions | 2 | 2024 | 31 | 0.100 |
Why?
| | Food, Genetically Modified | 1 | 2013 | 1 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2015 | 275 | 0.100 |
Why?
| | Food Labeling | 1 | 2013 | 5 | 0.100 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2013 | 4 | 0.100 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 22 | 0.100 |
Why?
| | Societies, Scientific | 1 | 2013 | 14 | 0.100 |
Why?
| | Nanospheres | 1 | 2013 | 4 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 182 | 0.100 |
Why?
| | Nanotechnology | 1 | 2013 | 31 | 0.100 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2013 | 46 | 0.100 |
Why?
| | Nutrition Policy | 1 | 2013 | 39 | 0.100 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1099 | 0.100 |
Why?
| | Mice, Inbred C57BL | 4 | 2020 | 1888 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 580 | 0.090 |
Why?
| | Blotting, Western | 1 | 2013 | 587 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 412 | 0.090 |
Why?
| | Film Dosimetry | 1 | 2012 | 15 | 0.090 |
Why?
| | Glucose | 2 | 2011 | 356 | 0.090 |
Why?
| | Surface Plasmon Resonance | 3 | 2017 | 19 | 0.090 |
Why?
| | Middle Aged | 6 | 2024 | 13133 | 0.090 |
Why?
| | RNA, Messenger | 2 | 2013 | 1134 | 0.090 |
Why?
| | Adult | 6 | 2024 | 14205 | 0.090 |
Why?
| | Gold Colloid | 2 | 2011 | 2 | 0.090 |
Why?
| | North Carolina | 2 | 2022 | 55 | 0.090 |
Why?
| | Acids | 1 | 2011 | 9 | 0.090 |
Why?
| | Isomerism | 1 | 2011 | 23 | 0.090 |
Why?
| | Gene Expression Regulation | 3 | 2021 | 1004 | 0.090 |
Why?
| | Immunohistochemistry | 2 | 2020 | 977 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2011 | 130 | 0.090 |
Why?
| | Copper | 1 | 2011 | 47 | 0.090 |
Why?
| | Aldehydes | 1 | 2011 | 81 | 0.090 |
Why?
| | Feces | 2 | 2024 | 159 | 0.090 |
Why?
| | Acenaphthenes | 1 | 2010 | 1 | 0.090 |
Why?
| | Nitrogen Oxides | 1 | 2010 | 3 | 0.090 |
Why?
| | Drug Screening Assays, Antitumor | 3 | 2024 | 135 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2013 | 318 | 0.080 |
Why?
| | Positron-Emission Tomography | 1 | 2012 | 297 | 0.080 |
Why?
| | Myosins | 1 | 2010 | 19 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2016 | 1140 | 0.080 |
Why?
| | Bone Transplantation | 1 | 2010 | 42 | 0.080 |
Why?
| | Isoxazoles | 1 | 2009 | 15 | 0.080 |
Why?
| | Nitrous Acid | 1 | 2009 | 1 | 0.080 |
Why?
| | Free Radicals | 1 | 2009 | 27 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 71 | 0.080 |
Why?
| | Actins | 1 | 2010 | 112 | 0.080 |
Why?
| | Acetylcysteine | 1 | 2010 | 101 | 0.080 |
Why?
| | Microcirculation | 1 | 2010 | 64 | 0.080 |
Why?
| | Aged | 5 | 2022 | 10242 | 0.080 |
Why?
| | Protein Transport | 1 | 2010 | 172 | 0.080 |
Why?
| | Naphthalenes | 1 | 2010 | 120 | 0.080 |
Why?
| | Formaldehyde | 1 | 2009 | 51 | 0.080 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2009 | 57 | 0.080 |
Why?
| | Young Adult | 3 | 2024 | 4346 | 0.080 |
Why?
| | Coculture Techniques | 2 | 2020 | 142 | 0.080 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2016 | 122 | 0.080 |
Why?
| | Glycolysis | 2 | 2021 | 70 | 0.080 |
Why?
| | Prospective Studies | 3 | 2023 | 2433 | 0.080 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2009 | 37 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 | 2 | 2008 | 21 | 0.070 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2008 | 10 | 0.070 |
Why?
| | Growth Inhibitors | 2 | 2009 | 26 | 0.070 |
Why?
| | Up-Regulation | 2 | 2007 | 462 | 0.070 |
Why?
| | Methotrexate | 1 | 2009 | 76 | 0.070 |
Why?
| | Evoked Potentials, Auditory, Brain Stem | 1 | 2008 | 26 | 0.070 |
Why?
| | Nerve Tissue Proteins | 2 | 2020 | 201 | 0.070 |
Why?
| | STAT3 Transcription Factor | 2 | 2020 | 89 | 0.070 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2009 | 140 | 0.070 |
Why?
| | Drinking | 2 | 2020 | 42 | 0.070 |
Why?
| | Alkynes | 1 | 2008 | 6 | 0.070 |
Why?
| | Pyrrolidines | 1 | 2008 | 65 | 0.070 |
Why?
| | Cytotoxins | 1 | 2008 | 15 | 0.070 |
Why?
| | Regional Blood Flow | 2 | 2005 | 109 | 0.070 |
Why?
| | Cryosurgery | 2 | 2011 | 36 | 0.070 |
Why?
| | Drug Synergism | 2 | 2005 | 147 | 0.070 |
Why?
| | Chemical Fractionation | 1 | 2007 | 17 | 0.070 |
Why?
| | Fluorescence | 2 | 2018 | 31 | 0.070 |
Why?
| | Skin | 2 | 2009 | 416 | 0.070 |
Why?
| | Toxicity Tests | 1 | 2008 | 57 | 0.070 |
Why?
| | Cost-Benefit Analysis | 2 | 2021 | 271 | 0.070 |
Why?
| | Oxidative Stress | 1 | 2012 | 805 | 0.070 |
Why?
| | Enzyme Activation | 2 | 2005 | 269 | 0.070 |
Why?
| | In Situ Nick-End Labeling | 2 | 2004 | 54 | 0.070 |
Why?
| | Histones | 2 | 2020 | 315 | 0.070 |
Why?
| | Sesquiterpenes | 1 | 2008 | 89 | 0.070 |
Why?
| | Sulfides | 2 | 2018 | 29 | 0.070 |
Why?
| | Neurons | 2 | 2020 | 442 | 0.070 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2008 | 80 | 0.060 |
Why?
| | Angiopoietin-2 | 2 | 2017 | 14 | 0.060 |
Why?
| | Angiopoietin-1 | 2 | 2017 | 16 | 0.060 |
Why?
| | Concept Formation | 1 | 2006 | 13 | 0.060 |
Why?
| | Fibroblast Growth Factor 2 | 2 | 2017 | 35 | 0.060 |
Why?
| | Lasers | 2 | 2019 | 64 | 0.060 |
Why?
| | Wetlands | 2 | 2017 | 5 | 0.060 |
Why?
| | Interleukin-2 | 1 | 2006 | 69 | 0.060 |
Why?
| | Coral Reefs | 2 | 2017 | 3 | 0.060 |
Why?
| | Interleukin-8 | 1 | 2006 | 86 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 2 | 2017 | 88 | 0.060 |
Why?
| | Sarcoma | 1 | 2007 | 68 | 0.060 |
Why?
| | Temperature | 3 | 2018 | 166 | 0.060 |
Why?
| | Mice, Inbred A | 2 | 2003 | 14 | 0.060 |
Why?
| | Signal-To-Noise Ratio | 1 | 2025 | 22 | 0.060 |
Why?
| | Feasibility Studies | 2 | 2022 | 404 | 0.060 |
Why?
| | Electrophoresis | 1 | 2005 | 16 | 0.060 |
Why?
| | Sensitivity and Specificity | 3 | 2016 | 871 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2007 | 230 | 0.060 |
Why?
| | Neoadjuvant Therapy | 2 | 2017 | 124 | 0.060 |
Why?
| | Tumor Suppressor Proteins | 1 | 2006 | 127 | 0.060 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 64 | 0.060 |
Why?
| | Electricity | 1 | 2025 | 7 | 0.060 |
Why?
| | Carbon | 1 | 2005 | 60 | 0.060 |
Why?
| | Alkanes | 1 | 2005 | 10 | 0.060 |
Why?
| | Neoplasm Staging | 2 | 2019 | 768 | 0.060 |
Why?
| | Public Policy | 2 | 2015 | 38 | 0.060 |
Why?
| | Colorectal Neoplasms | 2 | 2006 | 286 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 148 | 0.060 |
Why?
| | Photoacoustic Techniques | 2 | 2016 | 22 | 0.060 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 71 | 0.060 |
Why?
| | Cell Cycle Proteins | 1 | 2006 | 168 | 0.060 |
Why?
| | Niacinamide | 1 | 2005 | 24 | 0.060 |
Why?
| | Transplantation, Heterologous | 2 | 2021 | 78 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 639 | 0.060 |
Why?
| | Organelles | 1 | 2024 | 11 | 0.060 |
Why?
| | Protozoan Proteins | 1 | 2024 | 33 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2009 | 1365 | 0.060 |
Why?
| | Rats, Inbred F344 | 1 | 2005 | 194 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2005 | 106 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2024 | 49 | 0.050 |
Why?
| | Amines | 1 | 2004 | 38 | 0.050 |
Why?
| | MCF-7 Cells | 1 | 2024 | 63 | 0.050 |
Why?
| | Lichen Planus, Oral | 1 | 2004 | 1 | 0.050 |
Why?
| | Materials Testing | 1 | 2024 | 55 | 0.050 |
Why?
| | Leukoplakia, Oral | 1 | 2004 | 6 | 0.050 |
Why?
| | Kidney Diseases | 1 | 2007 | 230 | 0.050 |
Why?
| | Drug Combinations | 2 | 2018 | 136 | 0.050 |
Why?
| | Photochemistry | 1 | 2004 | 8 | 0.050 |
Why?
| | Buthionine Sulfoximine | 1 | 2024 | 13 | 0.050 |
Why?
| | Binding Sites | 2 | 2021 | 379 | 0.050 |
Why?
| | Hydrocarbons | 1 | 2004 | 14 | 0.050 |
Why?
| | Biological Availability | 1 | 2024 | 107 | 0.050 |
Why?
| | Cations | 1 | 2023 | 9 | 0.050 |
Why?
| | Carboplatin | 1 | 2024 | 55 | 0.050 |
Why?
| | Phosphorylation | 3 | 2017 | 536 | 0.050 |
Why?
| | Monoterpenes | 1 | 2003 | 5 | 0.050 |
Why?
| | Biocompatible Materials | 1 | 2024 | 67 | 0.050 |
Why?
| | Photosensitizing Agents | 1 | 2023 | 20 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2004 | 199 | 0.050 |
Why?
| | Crystallography, X-Ray | 2 | 2018 | 158 | 0.050 |
Why?
| | Mass Spectrometry | 2 | 2019 | 294 | 0.050 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2024 | 83 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 112 | 0.050 |
Why?
| | Organic Chemicals | 1 | 2003 | 15 | 0.050 |
Why?
| | Hepatitis B virus | 1 | 2023 | 20 | 0.050 |
Why?
| | Sphingomyelin Phosphodiesterase | 1 | 2003 | 11 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 34 | 0.050 |
Why?
| | DNA-Binding Proteins | 1 | 2006 | 423 | 0.050 |
Why?
| | G2 Phase | 1 | 2003 | 14 | 0.050 |
Why?
| | Prognosis | 2 | 2009 | 2100 | 0.050 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 263 | 0.050 |
Why?
| | Mammary Neoplasms, Animal | 1 | 2003 | 33 | 0.050 |
Why?
| | Quinazolines | 1 | 2003 | 32 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 2 | 2016 | 38 | 0.050 |
Why?
| | Analysis of Variance | 1 | 2004 | 558 | 0.050 |
Why?
| | Anions | 1 | 2022 | 7 | 0.050 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2004 | 224 | 0.050 |
Why?
| | Consensus | 1 | 2023 | 195 | 0.050 |
Why?
| | Interferons | 1 | 2022 | 38 | 0.050 |
Why?
| | Injections, Epidural | 1 | 2022 | 10 | 0.050 |
Why?
| | Acetone | 1 | 2022 | 7 | 0.050 |
Why?
| | Osteocalcin | 1 | 2022 | 44 | 0.050 |
Why?
| | Rifampin | 1 | 2022 | 58 | 0.050 |
Why?
| | Probability | 2 | 2016 | 171 | 0.050 |
Why?
| | Hepatocytes | 1 | 2023 | 184 | 0.050 |
Why?
| | Polyphosphates | 1 | 2022 | 2 | 0.050 |
Why?
| | Pain Measurement | 1 | 2023 | 263 | 0.050 |
Why?
| | Heating | 1 | 2022 | 5 | 0.050 |
Why?
| | Inositol | 1 | 2022 | 18 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 24 | 0.050 |
Why?
| | Propionates | 1 | 2002 | 23 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2022 | 1223 | 0.050 |
Why?
| | Hydrocortisone | 1 | 2022 | 112 | 0.050 |
Why?
| | Demography | 1 | 2022 | 92 | 0.050 |
Why?
| | Ferrets | 1 | 2021 | 7 | 0.050 |
Why?
| | Protein Isoforms | 1 | 2022 | 127 | 0.050 |
Why?
| | Estuaries | 1 | 2021 | 2 | 0.040 |
Why?
| | Bays | 1 | 2021 | 2 | 0.040 |
Why?
| | Hydrodynamics | 1 | 2021 | 8 | 0.040 |
Why?
| | San Francisco | 1 | 2021 | 12 | 0.040 |
Why?
| | Models, Economic | 1 | 2021 | 16 | 0.040 |
Why?
| | Pain Management | 1 | 2023 | 187 | 0.040 |
Why?
| | Income | 1 | 2022 | 106 | 0.040 |
Why?
| | Catalytic Domain | 1 | 2021 | 61 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2021 | 91 | 0.040 |
Why?
| | Protein Structure, Tertiary | 2 | 2017 | 260 | 0.040 |
Why?
| | Cricetinae | 1 | 2021 | 189 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2024 | 336 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2021 | 3449 | 0.040 |
Why?
| | Cell Division | 1 | 2002 | 288 | 0.040 |
Why?
| | Half-Life | 1 | 2021 | 86 | 0.040 |
Why?
| | Phosphates | 1 | 2021 | 51 | 0.040 |
Why?
| | Analgesics, Opioid | 1 | 2007 | 601 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2021 | 73 | 0.040 |
Why?
| | Micronucleus Tests | 1 | 2020 | 6 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 122 | 0.040 |
Why?
| | ROC Curve | 1 | 2021 | 249 | 0.040 |
Why?
| | Cell Line, Transformed | 1 | 2021 | 74 | 0.040 |
Why?
| | Software | 2 | 2016 | 281 | 0.040 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 93 | 0.040 |
Why?
| | Skin Temperature | 1 | 2020 | 17 | 0.040 |
Why?
| | Feedback, Physiological | 1 | 2020 | 13 | 0.040 |
Why?
| | Catecholamines | 1 | 2020 | 44 | 0.040 |
Why?
| | Limbic Encephalitis | 1 | 2020 | 2 | 0.040 |
Why?
| | Elastin | 1 | 2020 | 23 | 0.040 |
Why?
| | Monte Carlo Method | 1 | 2020 | 89 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 63 | 0.040 |
Why?
| | ADAM Proteins | 1 | 2020 | 21 | 0.040 |
Why?
| | HeLa Cells | 1 | 2020 | 243 | 0.040 |
Why?
| | Autoantigens | 1 | 2020 | 47 | 0.040 |
Why?
| | Epitopes | 1 | 2020 | 62 | 0.040 |
Why?
| | Antiviral Agents | 1 | 2021 | 173 | 0.040 |
Why?
| | Bone Density | 1 | 2022 | 396 | 0.040 |
Why?
| | Muscle Contraction | 1 | 2020 | 109 | 0.040 |
Why?
| | Cytoprotection | 1 | 2019 | 32 | 0.040 |
Why?
| | Facility Design and Construction | 1 | 2019 | 3 | 0.040 |
Why?
| | Endothelium | 1 | 2019 | 38 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2019 | 59 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2002 | 208 | 0.040 |
Why?
| | Energy Intake | 1 | 2020 | 183 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 57 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2020 | 183 | 0.040 |
Why?
| | Glioma | 1 | 2020 | 83 | 0.040 |
Why?
| | Skin Neoplasms | 1 | 2004 | 496 | 0.040 |
Why?
| | Swine | 2 | 2011 | 428 | 0.040 |
Why?
| | Diffusion Chambers, Culture | 1 | 2018 | 7 | 0.040 |
Why?
| | Culture Media, Serum-Free | 1 | 2018 | 11 | 0.040 |
Why?
| | Program Development | 1 | 2019 | 164 | 0.040 |
Why?
| | Culture Media, Conditioned | 1 | 2018 | 46 | 0.040 |
Why?
| | Hep G2 Cells | 1 | 2018 | 38 | 0.040 |
Why?
| | Laminin | 1 | 2018 | 20 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2004 | 2294 | 0.040 |
Why?
| | Flavin-Adenine Dinucleotide | 1 | 2018 | 4 | 0.040 |
Why?
| | Dextrans | 1 | 2018 | 16 | 0.040 |
Why?
| | Specimen Handling | 1 | 2018 | 59 | 0.040 |
Why?
| | Allosteric Site | 1 | 2018 | 2 | 0.040 |
Why?
| | Calcium-Binding Proteins | 1 | 2018 | 59 | 0.040 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 35 | 0.040 |
Why?
| | Surface Properties | 1 | 2018 | 61 | 0.040 |
Why?
| | Body Weight | 1 | 2020 | 524 | 0.040 |
Why?
| | NAD | 1 | 2018 | 46 | 0.040 |
Why?
| | Hippocampus | 1 | 2020 | 231 | 0.040 |
Why?
| | Proteoglycans | 1 | 2018 | 86 | 0.040 |
Why?
| | Imides | 1 | 2018 | 1 | 0.040 |
Why?
| | Mid-Atlantic Region | 1 | 2017 | 4 | 0.040 |
Why?
| | New England | 1 | 2017 | 10 | 0.040 |
Why?
| | Autophagy | 1 | 2019 | 185 | 0.040 |
Why?
| | Carbohydrates | 1 | 2018 | 41 | 0.030 |
Why?
| | Human Activities | 1 | 2017 | 7 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2017 | 11 | 0.030 |
Why?
| | Caco-2 Cells | 1 | 2017 | 31 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 235 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2018 | 111 | 0.030 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2018 | 86 | 0.030 |
Why?
| | Ligands | 1 | 2018 | 205 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2019 | 224 | 0.030 |
Why?
| | Ubiquitin | 1 | 2018 | 70 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2018 | 202 | 0.030 |
Why?
| | Nanotubes | 1 | 2017 | 17 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 271 | 0.030 |
Why?
| | Phagocytosis | 1 | 2017 | 54 | 0.030 |
Why?
| | Drug Interactions | 1 | 2017 | 198 | 0.030 |
Why?
| | Collagen | 1 | 2018 | 215 | 0.030 |
Why?
| | Disasters | 1 | 2017 | 19 | 0.030 |
Why?
| | Inflammation | 1 | 2021 | 649 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2017 | 48 | 0.030 |
Why?
| | Cricetulus | 1 | 2017 | 100 | 0.030 |
Why?
| | Cohort Studies | 1 | 2021 | 1576 | 0.030 |
Why?
| | Gene Frequency | 1 | 2017 | 97 | 0.030 |
Why?
| | CHO Cells | 1 | 2017 | 123 | 0.030 |
Why?
| | Pyrazoles | 1 | 2018 | 116 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 404 | 0.030 |
Why?
| | Fires | 1 | 2016 | 15 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 245 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2016 | 8 | 0.030 |
Why?
| | DNA Repair | 1 | 2018 | 194 | 0.030 |
Why?
| | Taxoids | 1 | 2016 | 38 | 0.030 |
Why?
| | Interleukin-1alpha | 1 | 2016 | 10 | 0.030 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2016 | 25 | 0.030 |
Why?
| | Radiation Pneumonitis | 1 | 2016 | 11 | 0.030 |
Why?
| | Poisson Distribution | 1 | 2016 | 37 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2016 | 68 | 0.030 |
Why?
| | Hindlimb Suspension | 1 | 2016 | 37 | 0.030 |
Why?
| | Diet | 1 | 2020 | 591 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 400 | 0.030 |
Why?
| | Particle Accelerators | 1 | 2016 | 51 | 0.030 |
Why?
| | Dicumarol | 2 | 2005 | 3 | 0.030 |
Why?
| | Palinuridae | 1 | 2015 | 1 | 0.030 |
Why?
| | Belize | 1 | 2015 | 2 | 0.030 |
Why?
| | Marine Biology | 1 | 2015 | 3 | 0.030 |
Why?
| | Receptors, Estrogen | 1 | 2016 | 133 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 2016 | 176 | 0.030 |
Why?
| | Ecology | 1 | 2015 | 18 | 0.030 |
Why?
| | Carbonic Anhydrases | 1 | 2015 | 3 | 0.030 |
Why?
| | Molecular Structure | 2 | 2008 | 317 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2015 | 59 | 0.030 |
Why?
| | Recreation | 1 | 2015 | 21 | 0.030 |
Why?
| | Muscular Atrophy | 1 | 2016 | 73 | 0.030 |
Why?
| | Genotype | 1 | 2017 | 563 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2018 | 315 | 0.030 |
Why?
| | Sulfur Dioxide | 1 | 2015 | 4 | 0.030 |
Why?
| | Models, Animal | 1 | 2016 | 230 | 0.030 |
Why?
| | Norepinephrine | 1 | 2015 | 106 | 0.030 |
Why?
| | Epinephrine | 1 | 2015 | 92 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2017 | 903 | 0.030 |
Why?
| | Risk | 1 | 2015 | 315 | 0.030 |
Why?
| | Weight Gain | 1 | 2016 | 235 | 0.030 |
Why?
| | Feeding Behavior | 1 | 2016 | 189 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 2 | 2004 | 74 | 0.030 |
Why?
| | Culture Media | 2 | 2004 | 96 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 816 | 0.030 |
Why?
| | Models, Immunological | 1 | 2013 | 8 | 0.030 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 33 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 579 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2013 | 73 | 0.020 |
Why?
| | Decision Making | 1 | 2015 | 273 | 0.020 |
Why?
| | Light | 1 | 2013 | 50 | 0.020 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2013 | 75 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2016 | 1558 | 0.020 |
Why?
| | Algorithms | 1 | 2016 | 673 | 0.020 |
Why?
| | Mutation | 1 | 2018 | 1331 | 0.020 |
Why?
| | Computer-Aided Design | 1 | 2011 | 20 | 0.020 |
Why?
| | Equipment Failure Analysis | 1 | 2011 | 44 | 0.020 |
Why?
| | Adjuvants, Pharmaceutic | 1 | 2011 | 5 | 0.020 |
Why?
| | Phantoms, Imaging | 1 | 2011 | 118 | 0.020 |
Why?
| | Equipment Design | 1 | 2011 | 287 | 0.020 |
Why?
| | Volatilization | 1 | 2010 | 5 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2010 | 71 | 0.020 |
Why?
| | Solvents | 1 | 2010 | 32 | 0.020 |
Why?
| | Geography | 1 | 2010 | 65 | 0.020 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2009 | 33 | 0.020 |
Why?
| | Air | 1 | 2009 | 22 | 0.020 |
Why?
| | Amides | 1 | 2009 | 36 | 0.020 |
Why?
| | Dogs | 1 | 2009 | 183 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 6694 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2009 | 68 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2009 | 21 | 0.020 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 25 | 0.020 |
Why?
| | Thermal Conductivity | 1 | 2009 | 7 | 0.020 |
Why?
| | Mammary Glands, Animal | 1 | 2009 | 68 | 0.020 |
Why?
| | Binding, Competitive | 1 | 2009 | 92 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2010 | 333 | 0.020 |
Why?
| | Pharmacokinetics | 1 | 2008 | 14 | 0.020 |
Why?
| | Models, Statistical | 1 | 2010 | 230 | 0.020 |
Why?
| | Child | 1 | 2021 | 7194 | 0.020 |
Why?
| | Guinea Pigs | 1 | 2008 | 76 | 0.020 |
Why?
| | Drug Design | 1 | 2009 | 122 | 0.020 |
Why?
| | Bone Marrow | 1 | 2010 | 354 | 0.020 |
Why?
| | Isatin | 1 | 2008 | 1 | 0.020 |
Why?
| | Auditory Threshold | 1 | 2008 | 54 | 0.020 |
Why?
| | Weight Loss | 1 | 2010 | 257 | 0.020 |
Why?
| | Glycosylphosphatidylinositols | 1 | 2007 | 14 | 0.020 |
Why?
| | Recurrence | 1 | 2009 | 680 | 0.020 |
Why?
| | Rubidium | 1 | 2006 | 4 | 0.020 |
Why?
| | Isoelectric Point | 1 | 2005 | 4 | 0.010 |
Why?
| | Isoelectric Focusing | 1 | 2005 | 8 | 0.010 |
Why?
| | Peptide Mapping | 1 | 2005 | 25 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2009 | 1045 | 0.010 |
Why?
| | Caffeine | 1 | 2006 | 69 | 0.010 |
Why?
| | Air Movements | 1 | 2005 | 1 | 0.010 |
Why?
| | Liver | 1 | 2011 | 1150 | 0.010 |
Why?
| | Cell Cycle | 1 | 2006 | 236 | 0.010 |
Why?
| | Quality Control | 1 | 2005 | 98 | 0.010 |
Why?
| | Tumor Stem Cell Assay | 1 | 2004 | 16 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2007 | 347 | 0.010 |
Why?
| | Tennessee | 1 | 2003 | 37 | 0.010 |
Why?
| | HL-60 Cells | 1 | 2003 | 19 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2009 | 570 | 0.010 |
Why?
| | Solubility | 1 | 2003 | 81 | 0.010 |
Why?
| | Cyclin B | 1 | 2003 | 4 | 0.010 |
Why?
| | CDC2 Protein Kinase | 1 | 2003 | 15 | 0.010 |
Why?
| | Cyclin B1 | 1 | 2003 | 7 | 0.010 |
Why?
| | Water | 1 | 2003 | 87 | 0.010 |
Why?
| | Heat-Shock Proteins | 1 | 2003 | 105 | 0.010 |
Why?
|
|
Griffin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|